B
Bo Gao
Researcher at University of Sydney
Publications - 28
Citations - 2860
Bo Gao is an academic researcher from University of Sydney. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 14, co-authored 28 publications receiving 1586 citations. Previous affiliations of Bo Gao include Millennium Institute & Westmead Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurélien Marabelle,Dung T. Le,Paolo A. Ascierto,Anna Maria Di Giacomo,Ana De Jesus-Acosta,Jean Pierre Delord,Ravit Geva,Maya Gottfried,Nicolas Penel,Aaron R. Hansen,Sarina Anne Piha-Paul,Toshihiko Doi,Bo Gao,Hyun Cheol Chung,Jose A. Lopez-Martin,Yung-Jue Bang,Ronnie Shapira Frommer,Manisha H. Shah,Razi Ghori,Andrew K. Joe,Scott K. Pruitt,Luis A. Diaz +21 more
TL;DR: The study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer.
Journal ArticleDOI
Dose-Response Association of CD8(+) Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Ellen L. Goode,Matthew S. Block,Kimberly R. Kalli,Robert A. Vierkant,Wenqian Chen,Zachary C. Fogarty,Aleksandra Gentry-Maharaj,A. Toloczko,Alexander Hein,Aliecia L. Bouligny,Aliecia L. Bouligny,Allan Jensen,Ana Osorio,Andreas D. Hartkopf,Andy Ryan,Anita Chudecka-Głaz,Anthony M. Magliocco,Arndt Hartmann,Audrey Y. Jung,Bo Gao,Brenda Y. Hernandez,Brooke L. Fridley,Bryan M. McCauley,Catherine J. Kennedy,Catherine J. Kennedy,Chen Wang,Chloe Karpinskyj,Christiani Bisinoto de Sousa,Daniel Guimarães Tiezzi,David L. Wachter,Esther Herpel,Florin Andrei Taran,Francesmary Modugno,Gregg Nelson,Jan Lubinski,Janusz Menkiszak,Jennifer Alsop,Jenny Lester,Jesús García-Donas,Jill Nation,Jillian Hung,Jillian Hung,José Palacios,Joseph H. Rothstein,Joseph L. Kelley,Jurandyr Moreira de Andrade,Luis Robles-Díaz,Maria P. Intermaggio,Martin Widschwendter,Matthias W. Beckmann,Matthias Ruebner,Mercedes Jimenez-Linan,Naveena Singh,Oleg Oszurek,Paul R. Harnett,Peter F Rambau,Peter F Rambau,Peter Sinn,Philipp Wagner,Prafull Ghatage,Raghwa Sharma,Raghwa Sharma,Robert P. Edwards,Roberta B. Ness,Sandra Orsulic,Sara Y. Brucker,Sharon E. Johnatty,Teri A. Longacre,Ursula Eilber,Valerie McGuire,Weiva Sieh,Yanina Natanzon,Zheng Li,Zheng Li,Alice S. Whittemore,Anna deFazio,Anna deFazio,Annette Staebler,Beth Y. Karlan,Blake Gilks,David D.L. Bowtell,David D.L. Bowtell,David D.L. Bowtell,Estrid Høgdall,Francisco José Candido dos Reis,Helen Steed,Ian G. Campbell,Ian G. Campbell,Jacek Gronwald,Javier Benitez,Jennifer M Koziak,Jenny Chang-Claude,Jenny Chang-Claude,Kirsten B. Moysich,Linda E. Kelemen,Linda S. Cook,Marc T. Goodman,Maria J. Garcia,Peter A. Fasching,Peter A. Fasching,Stefan Kommoss,Suha Deen,Susanne K. Kjaer,Usha Menon,James D. Brenton,Paul D.P. Pharoah,Georgia Chenevix-Trench,David G. Huntsman,David G. Huntsman,Stacey J. Winham,Martin Köbel,Susan J. Ramus,Susan J. Ramus +112 more
TL;DR: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival and suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.
Journal ArticleDOI
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Hyun Cheol Chung,Sarina Anne Piha-Paul,Jose A. Lopez-Martin,Jan H.M. Schellens,Steven Kao,Wilson H. Miller,Wilson H. Miller,Jean Pierre Delord,Bo Gao,David Planchard,Maya Gottfried,Alona Zer,Shadia I. Jalal,Nicolas Penel,Janice M. Mehnert,Ignacio Matos,Jaafar Bennouna,Dong Wan Kim,Lei Xu,Suba Krishnan,Kevin Norwood,Patrick A. Ott +21 more
TL;DR: Pembrolizumab demonstrated durable antitumor activity in subset of patients with recurrent/metastatic SCLC who had ≥2 previous lines of therapy, regardless of PD-L1 expression.
Journal ArticleDOI
ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer
Ellen L. Hedditch,Bo Gao,Amanda J. Russell,Yi Lu,Catherine Emmanuel,Jonathan Beesley,Sharon E. Johnatty,Xiaoqing Chen,Paul R. Harnett,Joshy George,Rebekka T. Williams,Claudia Flemming,Diether Lambrechts,Evelyn Despierre,Sandrina Lambrechts,Ignace Vergote,Beth Y. Karlan,Jenny Lester,Sandra Orsulic,Christine Walsh,Peter A. Fasching,Peter A. Fasching,Matthias W. Beckmann,Arif B. Ekici,Alexander Hein,Keitaro Matsuo,Satoyo Hosono,Toru Nakanishi,Yasushi Yatabe,Tanja Pejovic,Yukie Bean,Florian Heitz,Florian Heitz,Philipp Harter,Andreas du Bois,Ira Schwaab,Estrid Høgdall,S.K. Kjaer,Allan Jensen,Claus Høgdall,Lene Lundvall,Svend Aage Engelholm,Bob Brown,James M. Flanagan,Michelle D Metcalf,Nadeem Siddiqui,Thomas A. Sellers,Brooke L. Fridley,Julie M. Cunningham,Joellen M. Schildkraut,Ed Iversen,Rachel Palmieri Weber,Andrew Berchuck,Ellen L. Goode,David D.L. Bowtell,Georgia Chenevix-Trench,Anna deFazio,Murray D. Norris,Stuart MacGregor,Michelle Haber,Michelle J. Henderson +60 more
TL;DR: In this article, the relationship between clinical outcomes and ABC transporter gene expression in two independent cohorts of high-grade serous EOC tumors was assessed with real-time quantitative polymerase chain reaction, analysis of expression microarray data, and immunohistochemistry.
Journal ArticleDOI
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
Hyun Cheol Chung,Jose A. Lopez-Martin,Stephen Chuan-Hao Kao,Wilson H. Miller,Willeke Ros,Bo Gao,Aurélien Marabelle,Maya Gottfried,Alona Zer,Jean-Pierre Delord,Nicolas Penel,Shadia I. Jalal,Lei Xu,Susan Zeigenfuss,Scott K. Pruitt,Sarina Anne Piha-Paul +15 more
TL;DR: The antitumor activity of pembrolizumab, an IgG4 anti-PD-1 monoclonal antibody, was evaluated in patients with SCLC in KEYNOTE-158 (NCT02628067), a phase 2 basket study of 11 patients.